This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Rare Disease Innovation & Partnering Summit
May 17-19, 2022
Delivered as a Hybrid EventRevere Hotel Boston Common • Boston, MA

Laura Randa
CEO and President at Toivoa Therapeutics

Profile

Laura E. Randa serves as Chief Executive Officer and President of Toivoa. Toivoa has a singular mission to improve the lives of disabled patients living with mental health issues, providing hope to patients and their families through validated digital therapeutics.

Ms. Randa is a seasoned health care and life sciences healthcare executive with three decades of experience building high-performing teams and leading commercial markets across the supply chain. Throughout her career in senior executive roles, she has been the strategic advisor to the CEO to several companies, provided corporate leadership, executed successful turnarounds, and held responsibility for multi-billion-dollar P&L’s. She has successfully lead teams of up to 250 people through product launches to maximize returns, with a focus on driving a fast trajectory to peak sales. Her diverse experience includes large biopharmaceuticals, biotech, managed care, government, specialty and retail pharmacy, hospital systems, public policy, healthcare services, and consulting.

Ms. Randa is a visionary commercial leader who knows how to raise capital communicating the value of the organization, help mentor the senior executive team leadership to deliver market innovation that drives revenue growth, profitability, and strengthens market positions.   Ms. Randa brings to the board room her commercial experience with 33 new brand drug launches in driving pre-launch activities early in the R&D cycle, including early engagement with customers to co-develop the product value proposition (aligning R&D, Medical and Commercial). Ms. Randa has deep experience about commercialization, reimbursement, and access strategies.

Ms. Randa serves as a Member of the Board of Directors for the American Association of People with Disabilities. She is also a founding member of the American Association of People with Disabilities’ new Disability Advisory Roundtable.  She serves as Co-Chair of the Executive Women in Business Capital Region, Women’s Health Executive Committee and Life Science Council Board member at Springboard Enterprises and serves as a strategic advisor to the CEO and Founder Hello Career Guru.

In 2020, Ms. Randa was on the Executive Leadership team and Vice President, Market Access, HEOR and Public Policy at Mycovia, a portfolio division of NovaQuest, a private equity company. Ms. Randa built the commercial infrastructure, the specialty provider sales, market access, HEOR, pricing and health systems teams, and introduced comprehensive performance analytics and cash management system to drive top line growth and manage the operating efficiencies of the bottom line.

From 2018 to 2019, Ms. Randa also served as Vice President, Market Access at Novartis, a global pharmaceutical company with global revenues more than $47B. Hired for her market access and corporate turnaround expertise, she successfully led a reorganization to a new commercial matrix model led by market access and reimbursement.  The commercial strategy led with strategy and negotiations with payers, 3PL and wholesalers, enabling strategic pricing actions that resulted in $400M in revenue growth and restructured agreements avoiding $700M in revenue loss. Ms. Randa also played a key leadership role in the $8.7B acquisition of AveXis, and was accountable for consolidating and streamlining payer customer facing roles. She served as a U.S. commercial committee member, led the reimbursement and coverage for the company’s launch into MS, and relaunch for Immunology and Cardiology and chaired the U.S. pricing committee. She effectively managed a $10B P&L across multiple verticals and with the Oncology and Sandoz divisions. Ms. Randa had oversight for government pricing and compliance with all internal corporate audit and SOX requirements. Additionally, Ms. Randa’s expertise in biotech and biopharma drove supply channel efficiency strategies. 

From 2014 to 2018, Ms. Randa held the position as Head of Payer Engagement at Regeneron, a high growth biotech company. Ms. Randa was hired to build Regeneron’s healthcare market presence and commercial capabilities. While working alongside the CEO and founder, Dr. Len Schleifer, Laura led the transformation from a small biotech company with a single ophthalmology commercialized drug to a biotechnology powerhouse with leading a successful launch of blockbuster Dupixent®, which is on track to surpass peak sales of $12B, generating billions in market capital, $1B in sales in year one with an innovative channel strategy.  Ms. Randa led C-Suite stakeholder engagements to build the Regeneron brand and product launches through payer innovation, personalized medicine and early clinical study design collaborations using Real World Evidence.  Ms. Randa led high-level strategic and commercial leadership role with the Regeneron Genetic Center championing a variety of general population and phenotype collaborations with payers, including gathering and analyzing genomic data, spearheading analytical reports, and collaborating on analog development to inform patient care.

From 2011 to 2013, Ms. Randa was Global Director, Vaccines for GSK. Recruited to transform business with national payers and the government, her teams effectively managed $4.5B in product revenues across vaccines and global business units. She drove the first-in-kind payer revenue-based P&Ls, and transformed C-suite engagements. She served as a key executive member on the world-wide policy & government and strategy & innovation vaccine teams.

Ms. Randa has also held senior commercial leadership roles at Abbott, EMD Serono and Avanir. Prior to her commercial biopharmaceutical and provider experience, in 1989-1996, Ms. Randa held a leadership appointment by both Governor Michael Castle (DE) and President Joe Biden, as the chairman of the DE Teacher’s Academy for Service-Learning board to build a newly created Department of Health and Human Services & Education joint division for the State of Delaware.

Ms. Randa has a Bachelor of Science degree from The Ohio State University and a Master’s in Public Administration from the University of Delaware, Biden School of Public Policy and Administration.  She is a member of the Women Business Leaders of the U.S. Health Care Industry Foundation (www.wbl.org). She also serves as a formal mentor for the PharmD & MBA programs for The Ohio State University.   She has completed executive leadership programs at the University of Pennsylvania in Executive Education. Ms. Randa has been recognized two times in PharmaVoice magazine as one of the 100 Most Inspiring Leaders in the Life Sciences in 2013 and 2018

In her free time, Laura and her husband enjoy tennis, hiking and spending family time with their 2 children.

Agenda Sessions

  • TECHNOLOGY SPOTLIGHT ● Developing and Scaling Digital Therapeutics for Rare Diseases

    9:15am

Speakers at this event